Bourgier et al. [62] also assessed 36-month breast fibrosis-free survival (BFFS) in 456 patients treatment by hormone therapy based on their RILA status and showed that patients with RILA < 12% and hormone therapy (tamoxifen or aromatase inhibitor) had a BFFS of 75% vs. 100% in the RILA > 12% group without hormone therapy (p = 0.004, hazard ratio 5.84 [95% CI: 1.8–19.1]). This evidence concerns the gene CYP19A1 and breast fibrosis.